HUTCHMED (China) (HUTCHMED (China)) Short Percentage of Float

View and export this data going back to 2016. Start your Free Trial

What is HUTCHMED (China) Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of HUTCHMED (China)'s Short Percentage of Float

For the Drug Manufacturers - Specialty & Generic subindustry, HUTCHMED (China)'s Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HUTCHMED (China)'s Short Percentage of Float Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HUTCHMED (China)'s Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where HUTCHMED (China)'s Short Percentage of Float falls into.

HUTCHMED (China) (HUTCHMED (China)) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HUTCHMED (China) Ltd (NAS:HCM) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

00013:Hong Kong HCM.GB:UK HCM:UK H7T2:Germany

Address

2 Queen's Road Central, 48th Floor, Cheung Kong Center, Hong Kong, HKG

Website

https://www.hutch-med.com

HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.